Search This Blog

Monday, February 2, 2026

Let Americans Control Their Health Care

 President Trump is right about one crucial point in the health care debate. Sending money through insurance companies has failed. Patients should control health care dollars, not Washington. Where his latest proposal goes wrong is in how to do it.

Trump’s call to redirect funds from insurers to individuals comes as families face higher costs following the expiration of pandemic-era Obamacare subsidies. That instinct recognizes a real problem.

Subsidies that flow through insurers insulate prices, weaken competition, and leave patients disconnected from costs. But using those same temporary subsidies as the vehicle to send money to individuals would move in the wrong direction by expanding government involvement and adding to deficit spending, rather than fixing the system’s underlying financing failure.

The problem in American health care is not a lack of spending. The United States already spends about $5 trillion a year, close to 20 percent of GDP, yet families still face rising premiums, growing deductibles, and shrinking access. The issue is not how much money is in the system. It is where that money goes and who controls it.

Under the Affordable Care Act, premium assistance takes the form of advanceable, refundable tax credits tied to a government-defined benchmark plan. Consumers never receive these dollars. Instead, the federal government directs taxpayer dollars as payments to insurance companies each month, automatically adjusting subsidies as premiums rise.

That structure, highlighted again as subsidies expired at the end of 2025, is precisely what disconnects patients from price signals and allows costs to climb unchecked.

Using expired pandemic-era Obamacare subsidies as the basis for a new individual payment system would lock in the same mistake. It would extend a temporary COVID policy, expand federal spending, and embed Washington even deeper into health care financing. That is not empowerment. It is rebranding the same approach with a different messenger.

The real opportunity lies elsewhere.

The largest pool of health care-related dollars is not on the ACA exchanges. It is in employer-sponsored health insurance, a system built on a tax exclusion created during World War II wage controls that has never been repealed.

Because compensation is routed through health insurers rather than paychecks, workers never see the money or control how it is spent. In 2025, the average annual premium for employer-sponsored family coverage reached nearly $27,000. Those are wages workers never receive.

If policymakers want to give money to people instead of insurance companies, that is where the reform must start.

Redirecting a few thousand dollars from exchange subsidies helps at the margins. Redirecting nearly $27,000 in hidden compensation would fundamentally change incentives throughout the system without increasing federal spending or deficits.

This distinction matters. Expanding subsidies requires more government, more bureaucracy, and more borrowing. Unlocking existing compensation does not. It simply allows workers to keep and control the money they earned.

An effective way to do that is through No-Limit Health Savings Accounts, where families can save and spend health care dollars tax-free, without arbitrary caps or micromanagement. Combined with voluntarily-chosen catastrophic insurance, this approach would help restore price competition and patient choice while reducing reliance on third-party payments (i.e., government subsidies or private insurance providers).

We know this works. Transparent cash-pay providers such as the Surgery Center of Oklahoma publish bundled prices and routinely deliver care at often half the cost (or lower!) than hospital systems that bill through insurance. Direct Primary Care practices offer same-day access and predictable pricing because they operate outside the subsidy-driven insurance model.

By contrast, expanding subsidies or imposing price controls reduces access and innovation.

Physician appointment wait times continue to grow nationwide, according to workforce data, while patients in heavily regulated systems face care delays and, in extreme cases, death by queue.

These outcomes are not accidents. They are the predictable result of third-party dominance and centralized payment rules.

Trump deserves credit for identifying the problem. Health care-related dollars should follow patients, not insurers. But the solution is not to revive pandemic-era subsidies or create new federal payment streams. That approach would deepen government control and worsen the fiscal outlook.

The money is already in the system. It just isn’t in patients’ hands.

Real reform means ending the employer-based tax distortion, letting workers control their compensation, and allowing families to choose how to spend their health care dollars. That is the foundation of the Empower Patients Initiative.

Empowerment comes from ownership, not subsidies. Health care does not need more Washington spending or regulations. It needs to trust patients with the money that already belongs to them.

Vance Ginn, Ph.D., is president of Ginn Economic Consulting, host of the Let People Prosper Show, fellow at more than 20 free-market organizations, and previously served as Chief Economist at the first Trump White House’s Office of Management and Budget (2019–2020). 

https://vanceginn.substack.com/p/let-americans-control-their-health

This One Bipartisan Bill Would Cut Billions in Medicare Waste

 Lawmakers in Washington talk a good game about rooting out wasteful government spending, especially in parts of the federal budget that fuel the national debt. Now, Congress has a chance to turn talk into action.

A bipartisan bill introduced by Senators Bill Cassidy (R-LA) and Jeff Merkley (D-OR) called the No Unreasonable Payments, Coding, or Diagnoses for the Elderly, or “No UPCODE Act” takes aim at one of the most expensive and abused programs in the federal government: Medicare Advantage. This legislation targets a long-running scheme by private insurance companies that allows them to bleed Medicare and taxpayers dry through systematic overbilling.

Medicare Advantage allows seniors to receive their Medicare benefits through private insurance plans. The government pays insurers a fixed, per enrollee amount each month to cover all medical services. In theory, this is supposed to save money by reducing incentives for unnecessary healthcare utilization.

In reality, this system rewards insurance companies not for delivering better care for seniors, but for exaggerating patient diagnoses on paper, with taxpayers left footing the bill. In 2025 alone, the government spent an estimated $84 billion more on Medicare Advantage beneficiaries than it would have if those same seniors were enrolled in the traditional Medicare program. Unfortunately, that year was not an outlier.

A shocking 2024 report by the nonpartisan agency that advises Congress on Medicare found that over an 18-year period, the additional government spending associated with Medicare Advantage reached a gargantuan $591 billion. That's roughly $4,300 per tax filer when adjusting for inflation, according to the Wall Street Journal.

This isn’t the result of a few isolated payment mishaps. The sheer scale of the money squandered points to a systemic problem with the Medicare Advantage payment structure itself.

These billions in wasted spending are the result of clever schemes by private insurers to make their beneficiaries appear sicker than they really are. This is made possible by the government’s payment formula, which increases monthly payments for patients with higher reported health risks.

It wasn’t long before insurance companies figured out they could game the system and boost their profit margins by fiddling with their patients’ medical codes to maximize payments from Medicare. Known as “upcoding,” this scheme inflates patient diagnoses while providing no additional medical care. For example, a patient with mild diabetes might be coded as having uncontrolled diabetes, which, in turn, allows the insurer to pocket a higher monthly payment without offering any extra treatment.

With more than half of Medicare’s 68 million beneficiaries now enrolled in private Medicare Advantage plans, allowing upcoding to continue unabated is a fiscal time bomb. Every inflated diagnosis chips away at the fund that pays for seniors’ hospital stays, which is currently projected to run out of money by 2033 if no reforms are enacted.

What makes this abuse so infuriating is how long it has been allowed to fester under lawmakers’ noses. Federal watchdogs such as the Department of Health and Human Services’s Office of Inspector General have repeatedly warned that insurers use chart reviews and in-home health assessments to inflate diagnoses that aren’t supported by follow-up doctor visits or treatment.

Addressing this issue does not require completely dismantling Medicare Advantage or limiting choice for seniors. It simply requires aligning the program’s reimbursement formula with reality. Including the No UPCODE Act in a second reconciliation package would allow Congress to strengthen Medicare’s finances without cutting care for seniors.

Currently, payments are based on just one year of patient diagnoses, which makes it easy for insurance plans to quickly exaggerate medical risks. By mandating two years of diagnostic data, this legislation provides a more accurate way to assess the efficacy of diagnoses and subsequent treatments.

The Senators’ proposal also prohibits insurers from adding diagnoses that come solely from chart reviews or in-home health assessments without supporting doctor visits. According to the Congressional Budget Office, the targeted reforms in this legislation could save taxpayers more than $100 billion over 10 years.

Making Medicare sustainable for future generations doesn’t mean taking away benefits from seniors. It does, however, require stopping large insurance companies from padding their profit margins with taxpayer dollars. With commonsense reforms like the No UPCODE Act, lawmakers can ensure that federal health programs reward care, not clever accounting gimmicks.

Alexander Ciccone is the Policy and Government Affairs Manager for the National Taxpayers Union

https://www.realclearhealth.com/articles/2026/02/02/this_one_bipartisan_bill_would_cut_billions_in_medicare_waste_1162370.html

ICE Drops $70 Million On Massive Arizona Warehouse To Detain And Deport Illegals

 by Steve Watson via Modernity.news,

Arizona is ground zero in the fight to reclaim U.S. borders, with ICE shelling out a whopping $70 million for a 418,000-square-foot warehouse in Surprise—the size of seven football fields—to process and detain illegal aliens targeted for deportation. The acquisition under the Trump administration marks a long-overdue shift from the chaos of unchecked migration that flooded communities under previous Democrat-led policies.

The Department of Homeland Security snapped up the sprawling industrial site near Dysart and Cactus roads in a cash deal completed January 23, as property records confirm. ICE plans to convert it into a 1,500-bed processing center, part of a broader push to expand detention capacity amid renewed focus on mass deportations.

Local officials in Surprise distanced themselves, stating they “do not participate in ICE operations” but can’t block federal authority. Yet the move has ignited fury from Arizona Democrats, who see it as a direct threat to their sanctuary-state dreams.

State Senator Analise Ortiz slammed the purchase as “abhorrent,” adding “It really should chill all of us because ICE is violating the US Constitution, which means none of us are safe, including United States citizens.”

The warehouse buy comes hot on the heels of Arizona Attorney General Kris Mayes’ inflammatory warnings to ICE agents, where she suggested citizens could legally shoot masked feds under the state’s Stand Your Ground law.

In a brazen display of anti-enforcement bias, Mayes told local media: “You have these masked Federal officers with very little identification, sometimes no identification, wearing plain clothes and masks. And we have a stand your ground law that says that if you reasonably believe that your life is in danger, and you’re in your house or your car or on your property, that you can defend yourself with lethal force.”

She doubled down, questioning how people would know if masked intruders are legitimate officers: “But how do you know they’re a peace officer? It becomes, did they reasonably know that they were a peace officer?” Mayes even boasted of her own gun ownership, implying she’d react the same way.

Republicans blasted her comments as dangerously irresponsible, with calls for resignation pouring in. Senate Majority Leader John Kavanagh demanded she retract and step down, while Congressman Abe Hamadeh accused her of justifying murder against federal agents. It’s classic leftist hypocrisy: championing gun rights only when it suits their agenda to sabotage border security.

Mayes also launched a webpage urging citizens to report and film alleged ICE misconduct, vowing to prosecute agents for “assault, murder, unlawful imprisonment” if they step out of line. She warned ICE to “keep your hands off of our tribal members,” positioning herself as a defender against federal overreach while ignoring the real victims—American communities ravaged by illegal immigration.

The new Arizona facility is just one piece of ICE’s aggressive warehouse-buying spree across the U.S., with the agency acquiring sites in at least eight states to ramp up detention networks. Recent purchases include a $102 million warehouse in Maryland and plans for an 8,500-bed mega-jail in El Paso, Texas, as part of a $45 billion effort to enforce immigration laws long ignored by deep-state bureaucrats.

While open-borders advocates howl in protest, this facility promises to bolster enforcement efforts, ensuring criminals and overstays are swiftly removed to protect American families and sovereignty.

https://www.zerohedge.com/political/ice-drops-70-million-massive-arizona-warehouse-detain-and-deport-illegals

Tenet Announces Accretive Transaction and Previews Strong 2025 Results

 Tenet Healthcare Corporation (NYSE: THC) today announced the completion of a strategic transaction with CommonSpirit Health involving Tenet’s Conifer Health Solutions subsidiary.

Key terms of the transaction include:

  • Payments totaling approximately $1.9 billion from CommonSpirit to Tenet in installments over the next three years
  • Approximately $540 million redemption payment from Conifer to CommonSpirit to address the elimination of CommonSpirit’s capital account and the redemption of CommonSpirit’s 23.8% equity stake in Conifer, retroactively effective January 1, 2026
  • Incremental Tenet earnings in 2026 as a result of the January 1, 2026 equity transfer that would otherwise have been paid to CommonSpirit
  • Conifer will continue to support CommonSpirit through the end of 2026 which will conclude Conifer’s services. The financial terms are consistent with the existing contract.

This transaction will result in a reduction of Tenet’s redeemable non-controlling interest and other liabilities on its balance sheet of approximately $885 million and an increase to Tenet’s additional paid in capital of approximately $305 million.

“CommonSpirit came together with Conifer and Tenet in this transaction to support our multiyear system integration strategy,” said Michael Browning, SEVP and CFO, CommonSpirit. “Conifer has been a strong and reliable revenue cycle partner since 2012, bringing consistency to a previously fragmented environment in the former Catholic Health Initiatives portfolio. Conifer meaningfully contributed to these hospitals achieving 100% of their cash collection goals. We are grateful for Conifer’s longstanding collaboration and wish them continued success in delivering value to other healthcare systems.”

Conifer will continue to accelerate its technology enabled services and onboarding of new clients, and we will continue to provide reliable service to CommonSpirit throughout the year.

“Tenet respects CommonSpirit’s strategic imperatives and decision to insource the revenue cycle operations currently served by Conifer. CommonSpirit worked closely with us to structure a mutually beneficial transaction that reflects our longstanding partnership and commitment to the joint venture,” said Saum Sutaria, M.D., Chairman and CEO, Tenet Healthcare. “The transaction will enable a thoughtful, collaborative transition over the coming year. Conifer is grateful for the opportunity to serve CommonSpirit's ministries and our team takes pride in contributing to a strong revenue cycle foundation for their future. We look forward to seeing CommonSpirit continue advancing its important mission in the communities it serves.”

This milestone gives Tenet greater flexibility to support Conifer’s long-term potential. Conifer will expand its investments in artificial intelligence, automation and global operating capabilities, reflecting its commitment to innovation and market leadership in revenue cycle management services.

Although Tenet’s financial statement close process is not yet fully completed, the Company currently estimates that its Adjusted EBITDA for the year ended December 31, 2025, will be at the upper end of its current Adjusted EBITDA guidance range of $4.47 billion to $4.57 billion. The results were driven, among other things, by strong same store revenue growth and disciplined expense management.

“We continue to deliver strong revenue growth, improved margins and attractive free cash flow as a result of effective execution of our strategies,” said Sutaria. “We look forward to providing more details on our performance when we announce our complete fourth quarter and full year 2025 results on February 11, 2026.”

The Company’s actual results for the year ended December 31, 2025 may differ from preliminary estimates and additional developments and adjustments may arise between now and the time the financial information for this period is finalized. Accordingly, you should not place undue reliance on these estimates.

Management’s Webcast Discussion of the Transaction

Tenet management will discuss this transaction in a webcast scheduled for 10:00 a.m. Eastern Time (9:00 a.m. Central Time) on February 2, 2026. Investors can access the webcast through the Company’s website at www.tenethealth.com/investors.

https://www.morningstar.com/news/business-wire/20260202205792/tenet-announces-accretive-transaction-and-previews-strong-2025-results

U.S. Physical Therapy Announces Strategic Alliance with NYU Langone Health

 U.S. Physical Therapy, Inc. (“USPH”) (NYSE, NYSE Texas: USPH), a national operator of outpatient physical therapy clinics and provider of industrial injury prevention services, announced a 10-year strategic alliance between its subsidiary partner, Metro Physical & Aquatic Therapy (“Metro Physical Therapy”), and NYU Langone Health, one of the nation’s top-ranked academic medical centers (“NYU Langone”). NYU Langone and Metro Physical Therapy will work together in Long Island and the New York metropolitan area to deliver exceptional physical therapy care to patients throughout the region.

This strategic move underscores NYU Langone’s commitment to expanding its health care network and to providing access to outpatient physical therapy services in collaboration with first-in-class providers such as Metro Physical Therapy. Through this agreement, Metro Physical Therapy’s existing 60 outpatient physical therapy clinics will become a part of NYU Langone’s clinical services network. It is anticipated that this alliance will become operational commencing within the next few months.

“Our Metro PT team, led by Michael Mayrsohn, is a perfect partner for NYU Langone to further grow the greater New York markets,” said Chris Reading, Chairman and CEO of USPH. “Both organizations are committed to providing exceptional care for patients while expanding the overall footprint for outpatient physical therapy services, extending access to these necessary services in neighboring communities.”

“We are excited to collaborate with USPH and Metro Physical Therapy to expand our outpatient physical therapy network across the New York City region," said Oren Cahlon, MD, Executive Vice President and Vice Dean for Clinical Affairs and Strategy, Chief Clinical Officer of NYU Langone. “Our goal is to enhance NYU Langone’s well-established physical therapy services. We have a shared vision to provide high-quality care and an outstanding patient experience.”

USPH will discuss the arrangement, including the financial impacts, on its year-end earnings release and conference call, which currently are scheduled for February 25 and 26, 2026, respectively.

https://www.morningstar.com/news/business-wire/20260202422553/us-physical-therapy-announces-strategic-alliance-with-nyu-langone-health

Twist Bioscience rises as fiscal 2026 revenue guidance raised

 Twist Bioscience Corporation (NASDAQ:TWST) reported fiscal first-quarter 2026 revenue that came in ahead of market expectations on Monday, prompting a rally in the stock, even though earnings fell short of forecasts.

Shares of the biotech group were up about 5.16% in premarket trading following the announcement.

Twist posted quarterly revenue of $103.7 million for the period ended December 31, 2025, beating the analyst consensus of $100.72 million and marking a 17% increase from $88.7 million a year earlier. The company, however, reported a net loss of $0.50 per share, wider than analysts’ expectations for a loss of $0.43 per share.

Encouraged by the stronger-than-expected top-line performance, management raised its full-year fiscal 2026 revenue guidance to a range of $435 million to $440 million, up from the prior outlook of $425 million to $435 million. The company also reiterated its goal of reaching adjusted EBITDA breakeven by the fourth quarter.

“We’re continuing to build on the momentum we established in fiscal 2025, starting the new fiscal year with our twelfth consecutive quarter of growth,” said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience. “Revenue of $103.7 million exceeded guidance and increased 17% compared to the first quarter of 2025.”

Profitability metrics also improved, with gross margin rising to 52.0% in the quarter, up roughly four percentage points from 48.3% in the same period last year. Twist shipped products to around 2,538 customers during the quarter, compared with 2,376 customers in the first quarter of fiscal 2025.

Looking ahead, the company expects second-quarter revenue of approximately $107 million to $108 million, implying about 16% year-on-year growth. Twist also said it anticipates gross margin will remain above 52% for the full 2026 fiscal year.

As of December 31, 2025, the company reported approximately $198 million in cash, cash equivalents and short-term investments.

https://www.msn.com/en-us/money/companies/twist-bioscience-shares-jump-5-after-revenue-tops-forecasts-and-outlook-is-lifted/ar-AA1Vv3VA

MoonLake (MLTX) Secures FDA Fast Track for Sonelokimab in PPP Treatment

 MoonLake Immunotherapeutics (MLTX) has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for its drug sonelokimab, aimed at treating moderate-to-severe palmoplantar pustulosis (PPP). The company's request for this designation was made on December 1, 2025. This news comes on the heels of successful discussions with the FDA, where MoonLake validated its clinical evidence strategy, aiming to submit a Biologics License Application (BLA) for sonelokimab in hidradenitis suppurativa (HS) in the latter half of 2026.

Additionally, MoonLake announced an Investor Day scheduled for February 23, 2026. The event will include comprehensive updates on clinical and regulatory progress across various indications, along with new data from the S-OLARIS study concerning sonelokimab in axial spondyloarthritis (axSpA).

https://www.gurufocus.com/news/8572866/moonlake-mltx-secures-fda-fast-track-for-sonelokimab-in-ppp-treatment